Form 4 Filing for Axsome Therapeutics, Inc.

This filing details a transaction by Mark E. Saad, a director at Axsome Therapeutics, Inc. (AXSM). On June 5, 2026, Mr. Saad acquired 1,721 Restricted Stock Units (RSUs) with a transaction value of $0. These RSUs represent a contingent right to receive one share of the Issuer's common stock. The RSUs vest in full on the one-year anniversary of the grant date. Following this transaction, Mr. Saad holds 1,721 shares of common stock. The filing was signed by Nick Pizzie, Attorney-in-Fact, on June 9, 2026.